An Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 18 Years of Age or Older With Solid Tumours Receiving Chemotherapy
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 237
- 试验地点
- 1
- 主要终点
- Number of Subjects With Any and Grade 3 Solicited Local Symptoms
研究概览
简要总结
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults with solid tumours undergoing chemotherapy.
详细描述
The study will be randomised into two groups based on the vaccination schedule in relation to the start of a chemotherapy cycle:
- The OnChemo group receives their first HZ/su vaccination at the start of a chemotherapy cycle,
- The PreChemo group receives their first HZ/su vaccination at least 10 days before the start of a chemotherapy cycle.
The protocol summary has been updated following Protocol Amendment 2, August 2014, leading to the increase of the enrolment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •Written informed consent obtained from the subject.
- •A male or female aged 18 years or older (and has reached the age of legal consent) at the time of study entry (i.e., when informed consent is signed).
- •Subject who has been diagnosed with one or more solid tumours (defined as a solid malignancy, i.e., not a blood element malignancy).
- •Subject who is receiving or will receive a cytotoxic or immunosuppressive chemotherapy (such that the study vaccine can be administered at the latest at the start of the second cycle of chemotherapy).
- •Life expectancy of greater than one year.
- •Female subjects of non-childbearing potential may be enrolled in the study:
- •Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause;
- •Female subjects of childbearing potential may be enrolled in the study, if the subject:
- •has practiced adequate contraception for 30 days prior to vaccination, and
- •has a negative pregnancy test on the day of vaccination, and
- •has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
排除标准
- •Subjects receiving only newer, more targeted therapies if not taken together with a classical chemotherapy.
- •Chronic administration and/or planned administration of systemic glucocorticoids within one month prior to the first vaccine dose and up to Visit 3 (Month 2). Inhaled, intra-articularly injected, and topical steroids are allowed.
- •Previous vaccination against HZ or varicella within 12 months preceding the first dose of study vaccine/ placebo.
- •Planned administration during the study of a HZ vaccine (including an investigational or non-registered vaccine) other than the study vaccine.
- •Previous chemotherapy course less than one month before first study vaccination.
- •Occurrence of a varicella or HZ episode by clinical history within the 12 months preceding the first dose of study vaccine/ placebo.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine or study material and equipment.
- •Administration or planned administration of a live vaccine in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.
- •HIV infection by clinical history.
- •Acute disease and/or fever at the time of vaccination. Acute disease is defined as the presence of a moderate or severe illness with or without fever, but excludes the underlying malignancy, as well as the expected symptoms/signs associated with that disease or its treatment:
- •Fever is defined as temperature ≥ 37.5°C /99.5°F on oral, axillary or tympanic setting, or ≥ 38.0°C /100.4°F on rectal setting. The preferred route for recording temperature in this study will be oral.
- •Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever, may receive the first dose of study vaccine/ placebo at the discretion of the investigator.
- •Any condition which, in the judgment of the investigator would make intramuscular injection unsafe.
- •Pregnant or lactating female.
- •Female planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) before Month 3 (i.e., 2 months after the last dose of study vaccine/ placebo).
研究组 & 干预措施
GSK1437173A Group
Subjects received the first dose of GSK 1437173A at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of GSK 1437173A vaccine was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
干预措施: GSK 1437173A (Biological)
Placebo Group
Subjects received the first dose of placebo at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of placebo was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
时间窗: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal every day activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Adjusted Geometric Means for Anti-glycoprotein E (gE) Antibodies in PreChemo Groups
时间窗: At Month 2
Adjusted geometric means (GMC) of GSK1437173A over placebo for anti-glycoprotein E (gE) antibody enzyme-linked immunosorbent assay (ELISA) concentrations in PreChemo Groups only.
Number of Days With Solicited Local Symptoms
时间窗: During the 7-day (Days 0-6) post-vaccination period following each dose
The number of days with any local symptoms has been assessed during the post-vaccination period.
Anti-Varicella Zoster Virus (VZV) gE Antibody Concentrations
时间窗: At Month 2
Antibody concentrations as determined by ELISA are presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (≥) 97 mIU//mL.
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
时间窗: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Assessed solicited general symptoms were fatigue, gastrointestinal \[symptoms included nausea, vomiting, diarrhoea and/or abdominal pain\], headache, myalgia, shivering and fever \[defined as oral, axillary or tympanic temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Number of Days With Solicited General Symptoms
时间窗: During the 7-day (Days 0-6) post-vaccination period following each dose
The number of days with any general symptoms has been assessed during the post-vaccination period.
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
时间窗: During the 30-day (Days 0-29) post-vaccination period
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Number of Subjects With Serious Adverse Events (SAEs)
时间窗: From first dose up to 30 days post last vaccination
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Related SAE= SAE assessed by the investigator as causally related to the study vaccination.
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
时间窗: From first vaccination up to 30 days post last vaccination
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMDs assessed by the investigator as causally related to the study vaccination.
次要结局
- Anti-VZV gE Antibody Concentrations(At Months 0, 1, 6 and 13)
- Descriptive Statistics of the Frequency of gE-specific CD4[2+] T-cells in PreChemo Groups(At Months 0, 1, 2 and 13)
- Number of Subjects With Serious Adverse Events (SAEs)(From 30 days post last vaccination up to study end (Month 13))
- Number of Subjects With Any Potential Immune Mediated Diseases (pIMDs)(From 30 days post last vaccination up to study end (Month 13))
- Number of Subjects With Vaccine Responses for Anti-gE Antibody ELISA Concentrations(At Months 1, 2, 6 and 13)
- Number of Subjects With Vaccine Responses for gE-specific CD4[2+] T-cells in PreChemo Groups(At Months 1, 2 and 13)